Usefulness of Simplified Pulmonary Embolism Severity Index Score for Identification of Patients With Low-Risk Pulmonary Embolism and Active Cancer
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Bayer HealthCare
- Bristol-Myers Squibb
- Mitsubishi Tanabe Pharma Corporation
This publication has 28 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: The POMPE-C toolThrombosis Research, 2012
- Prognostic clinical prediction rules to identify a low‐risk pulmonary embolism: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2012
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Outpatient treatment in patients with acute pulmonary embolism: the Hestia StudyJournal of Thrombosis and Haemostasis, 2011
- The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolismEuropean Respiratory Journal, 2010
- Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous ThromboembolismCirculation, 2008
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988